Rubrik has been upgraded to a buy rating due to its expanding market opportunities, strong profitability, and unique AI-driven cybersecurity solutions. The company reported a 39% year-over-year revenue increase in Q1, with normalized growth at 43%, gross margins improving to 83%, and net revenue retention at 120%. Although the FY2027 guidance indicates slower top-line growth, profitability is expected to improve, with the annual recurring revenue margin rising from 12% to 14%. The current valuation at 11 times forward price-to-sales ratio is considered reasonable, supporting long-term growth as Rubrik integrates with leading AI platforms.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
